Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have earned an average rating of “Buy” from the sixteen brokerages that are presently covering the stock. Three equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $183.43.

Several research firms recently commented on TMO. Jefferies Group LLC reiterated a “hold” rating and issued a $160.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, March 29th. Bank of America Corp upped their price target on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $160.00 to $162.00 and gave the company a “buy” rating in a research report on Tuesday, January 31st. BTIG Research upped their price target on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research report on Wednesday, February 1st.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $158.60, for a total value of $3,172,000.00. Following the transaction, the chief executive officer now directly owns 289,279 shares of the company’s stock, valued at approximately $45,879,649.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas W. Loewald sold 4,049 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $158.71, for a total transaction of $642,616.79. Following the completion of the transaction, the senior vice president now directly owns 42,809 shares in the company, valued at $6,794,216.39. The disclosure for this sale can be found here. Insiders sold a total of 62,652 shares of company stock worth $10,021,352 over the last three months. 0.52% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after buying an additional 22,165,530 shares in the last quarter. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $534,860,000. Glenview Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $516,388,000. C WorldWide Group Holding A S boosted its position in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock valued at $299,527,000 after buying an additional 1,772,300 shares in the last quarter. Finally, Veritas Asset Management LLP purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $175,795,000. 87.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/05/26/thermo-fisher-scientific-inc-tmo-receives-consensus-rating-of-buy-from-analysts.html.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.30% on Friday, reaching $173.42. 683,280 shares of the company’s stock were exchanged. Thermo Fisher Scientific has a one year low of $139.07 and a one year high of $173.64. The firm has a market capitalization of $67.85 billion, a P/E ratio of 31.63 and a beta of 1.10. The firm has a 50 day moving average of $164.60 and a 200 day moving average of $153.62.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $2.08 EPS for the quarter, beating the consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.06% and a return on equity of 15.41%. The firm had revenue of $4.77 billion during the quarter, compared to the consensus estimate of $4.68 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Thermo Fisher Scientific will post $9.22 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 17th. Shareholders of record on Thursday, June 15th will be paid a $0.15 dividend. The ex-dividend date is Tuesday, June 13th. This represents a $0.60 annualized dividend and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is currently 11.79%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

12 Month Chart for NYSE:TMO

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.